Is the UK NICE "reference case" influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations?

[1]  Sarah A. Edwards,et al.  Characteristics and quality of pediatric cost-utility analyses , 2012, Quality of Life Research.

[2]  T. Rautenberg,et al.  Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model , 2012, ClinicoEconomics and outcomes research : CEOR.

[3]  A. Melegaro,et al.  The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. , 2012, Vaccine.

[4]  J Brazier,et al.  NICE DSU Technical Support Document 8: An Introduction to the Measurement and Valuation of Health for NICE Submissions [Internet] , 2011 .

[5]  D. Baguley,et al.  Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation. , 2011, Health technology assessment.

[6]  S. Walker,et al.  Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. , 2011, Health technology assessment.

[7]  D. Price,et al.  A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). , 2011, Health technology assessment.

[8]  D. Craig,et al.  Growth monitoring for short stature: update of a systematic review and economic model. , 2011, Health technology assessment.

[9]  M. Connock,et al.  A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. , 2011, Health technology assessment.

[10]  C. Fidler,et al.  Cost‐effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice‐weekly maintenance treatment vs. standard twice‐daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective , 2011, The British journal of dermatology.

[11]  J. Bryant,et al.  Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. , 2010, Health technology assessment.

[12]  E. Juniper,et al.  Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma , 2010, PharmacoEconomics.

[13]  S. Petrou,et al.  Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  T. Christensen,et al.  Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. , 2010, Clinical therapeutics.

[15]  A. Q. Summerfield,et al.  Estimates of the Cost-Effectiveness of Pediatric Bilateral Cochlear Implantation , 2010, Ear and hearing.

[16]  Michael Herdman,et al.  Development of the EQ-5D-Y: a child-friendly version of the EQ-5D , 2010, Quality of Life Research.

[17]  D. Craig,et al.  Economic evaluation of enhanced staff contact for the promotion of breastfeeding for low birth weight infants , 2010, International Journal of Technology Assessment in Health Care.

[18]  M. Jit,et al.  Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. , 2010, Vaccine.

[19]  J. Lindsay,et al.  Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Wendy J. Ungar,et al.  Economic Evaluation in Child Health , 2010 .

[21]  M. Hoyle,et al.  The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. , 2009, Health technology assessment.

[22]  K. Stevens.  Developing a descriptive system for a new preference-based measure of health-related quality of life for children , 2009, Quality of Life Research.

[23]  D. Craig,et al.  Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis. , 2009, Health technology assessment.

[24]  Jennifer A. Roberts,et al.  Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. , 2009, Vaccine.

[25]  P. Garvie,et al.  Quality of life measurement in paediatric and adolescent populations with HIV: a review of the literature. , 2009, Child: care, health and development.

[26]  S. Prasad,et al.  Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK , 2009, International journal of clinical practice.

[27]  S. Bayliss,et al.  Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. , 2008, Health technology assessment.

[28]  M. Deverill,et al.  Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. , 2008, Health technology assessment.

[29]  M. Aristides,et al.  A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  J. Karnon,et al.  Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom* , 2008, Current medical research and opinion.

[31]  J Bamford,et al.  Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen. , 2007, Health technology assessment.

[32]  P. Glasziou,et al.  A systematic review of the routine monitoring of growth in children of primary school age to identify growth-related conditions. , 2007, Health technology assessment.

[33]  M. Jit,et al.  Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. , 2007, Vaccine.

[34]  S. Bryan,et al.  The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies , 2007, Seizure.

[35]  J. Raftery,et al.  A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. , 2006, Health technology assessment.

[36]  M Sculpher,et al.  Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model. , 2006, Health technology assessment.

[37]  Paula C. Stacey,et al.  Hearing-Impaired Children in the United Kingdom, IV: Cost-Effectiveness of Pediatric Cochlear Implantation , 2006, Ear and hearing.

[38]  A. O'Hagan,et al.  The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. , 2006, Health technology assessment.

[39]  M. Drummond,et al.  A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.

[40]  M. Pitt,et al.  A cost‐utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema , 2006, The British journal of dermatology.

[41]  M. Sculpher,et al.  Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. , 2005, Health technology assessment.

[42]  F. Sassi,et al.  The cost-effectiveness of neonatal screening for Cystic Fibrosis: an analysis of alternative scenarios using a decision model , 2005, Cost effectiveness and resource allocation : C/E.

[43]  R Garside,et al.  The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. , 2005, Health technology assessment.

[44]  J. Coast,et al.  Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health , 2005, Pediatrics.

[45]  D. Spiegelhalter,et al.  Issues in data monitoring and interim analysis of trials. , 2005, Health technology assessment.

[46]  C. Eiser,et al.  The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review , 2004, Health and quality of life outcomes.

[47]  A. Melegaro,et al.  Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. , 2004, Vaccine.

[48]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[49]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[50]  W. Ungar,et al.  The Pediatric Economic Database Evaluation (PEDE) Project: Establishing a Database to Study Trends in Pediatric Economic Evaluation , 2003, Medical care.

[51]  W. Ungar,et al.  The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  G. Guyatt,et al.  Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. , 1997, The European respiratory journal.

[53]  M. Nuijten,et al.  Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children , 2012, PharmacoEconomics.

[54]  S. Bayliss,et al.  Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. , 2011, Health technology assessment.

[55]  Y. Yi,et al.  Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox–Gastaut Syndrome in the United Kingdom , 2010, Seizure.

[56]  J. Cairns,et al.  Cost utility evaluation of extracorporeal membrane oxygenation as a bridge to transplant for children with end-stage heart failure due to dilated cardiomyopathy. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[57]  C. Eiser,et al.  Quality-of-life measures in chronic diseases of childhood. , 2001, Health technology assessment.